Back to top
more

Integra LifeSciences (IART)

(Delayed Data from NSDQ)

$29.24 USD

29.24
739,206

+0.90 (3.18%)

Updated Apr 29, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 46% (136 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's Why You Should Hold on to Integra (IART) Stock for Now

Investors are optimistic about Integra's (IART) better-than-expected results and robust segmental performance.

Integra's (IART) Q4 Earnings Top Estimates, Gross Margin Drops

Integra (IART) records strong recovery in order demand in Q4 on broad-based strength in Neurosurgery and sales from the company's new CereLink ICP monitoring.

Integra LifeSciences (IART) Q4 Earnings and Revenues Surpass Estimates

Integra (IART) delivered earnings and revenue surprises of 1.20% and 0.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Integra (IART) Announces Preliminary Q4 & '21 Sales Results

Integra's (IART) preliminary revenue results and recent plans to implement a $125-million share repurchase instill investor optimism.

Here's Why You Should Hold on to Integra (IART) Stock for Now

Investors are optimistic about Integra's (IART) strong third-quarter performance and ongoing recovery across its business.

Integra (IART) Businesses Rebound Despite Supply Issues

Integra's (IART) ongoing sales recovery across geographies and product lines looks encouraging.

Integra (IART) Down 13.2% Since Last Earnings Report: Can It Rebound?

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to Integra (IART) Stock for Now

Investors are optimistic about Integra (IART) given its better-than-expected results and robust performance of the CSS arm in the third quarter.

Integra (IART) Q3 Earnings Top Estimates, 2021 EPS View Up

Integra (IART) reports better-than-expected earnings and revenues with robust demand for the company's products driving the top line in third-quarter 2021.

Integra LifeSciences (IART) Q3 Earnings and Revenues Top Estimates

Integra (IART) delivered earnings and revenue surprises of 19.44% and 0.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Integra LifeSciences (IART) Q3 Earnings Expected to Decline

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integra (IART) Up 1.5% Since Last Earnings Report: Can It Continue?

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Integra (IART) Stock for Now

Solid performance across the CSS and Tissue Technologies segments is driving the top line for Integra (IART).

Integra (IART) Q2 Earnings Top Estimates, 2021 Guidance Up

Integra (IART) reports better-than-expected revenues with strong segmental performance driving the top line in second-quarter 2021.

Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates

Integra (IART) delivered earnings and revenue surprises of 17.91% and 3.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Device Stocks' Earnings on Jul 28: TMO, ALGN & More

The sector's Q2 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

Integra LifeSciences (IART) Earnings Expected to Grow: Should You Buy?

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integra (IART) Releases Favorable PriMatrix Clinical Outcome

Integra's (IART) PriMatrix study data validates that one application of PriMatrix is needed to address hard-to-heal diabetic foot ulcers.

Integra's (IART) SurgiMend Gets Innovative Technology Contract

Integra's (IART) SurgiMend Collagen Matrix is recognized as a product that can potentially bring improvement to the health care industry.

Integra (IART) Tissue Technologies Rebounds Amid Supply Woe

Integra's (IART) CSS segment too reflects a gradual recovery in procedure-based market as well as an improvement in hospital capital spending during the first quarter.

Integra (IART) Down 8.1% Since Last Earnings Report: Can It Rebound?

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ResMed (RMD) Q3 Earnings Surpass Estimates, Revenues Miss

Lower device sales including weak demand for ventilators due to COVID-19 hurt ResMed's (RMD) Q3 top line.

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Guidance Up

Bio-Rad's (BIO) first-quarter revenues improved year over year on robust growth in Life Science and Clinical Diagnostics segments.

Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up

Syneos Health (SYNH) registers sales uptick in its Clinical Solutions business on the back of favorable acquisition impacts and increased project start-up activities.